Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Stem Cells. Nov 26, 2025; 17(11): 113201
Published online Nov 26, 2025. doi: 10.4252/wjsc.v17.i11.113201
Published online Nov 26, 2025. doi: 10.4252/wjsc.v17.i11.113201
Role of human umbilical cord mesenchymal stem cells in diabetic kidney disease
Yan Liu, Xiao-Qian Shan, Yu-Jiao Li, Wei-Li Gao, Lan Zhao, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300381, China
Yan Liu, Xiao-Qian Shan, Yu-Jiao Li, Wei-Li Gao, Lan Zhao, National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin 300381, China
Author contributions: Liu Y wrote the manuscript; Shan XQ, Li YJ, Gao WL, and Zhao L revised the manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Lan Zhao, Academic Fellow, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, No. 88 Changling Road, Xiqing District, Tianjin 300381, China. lanzhao69@163.com
Received: August 19, 2025
Revised: September 17, 2025
Accepted: October 31, 2025
Published online: November 26, 2025
Processing time: 99 Days and 15.2 Hours
Revised: September 17, 2025
Accepted: October 31, 2025
Published online: November 26, 2025
Processing time: 99 Days and 15.2 Hours
Core Tip
Core Tip: This letter to the editor focuses on investigating how human umbilical cord mesenchymal stem cells (hUC-MSCs) contribute to diabetic kidney damage. At the same time, explore the similarities and differences of hUC-MSCs in treating metabolic dysfunction-associated steatotic liver disease and diabetic kidney disease. There are benefits of using hUC-MSCs to treat metabolic disorders. Future studies on the relationship between hUC-MSCs and the management of metabolic disorders ought to be promoted.